BOSTON SCIENTIFIC CORP — Form 8-K
Filed October 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Joseph M. Fitzgerald appointed Executive Vice President and Chief Operating Officer effective January 1, 2027, reporting to CEO Michael Mahoney. Compensation includes base salary of $1.05M annually, annual bonus target increased to 110% of base salary, and equity award of $7M (combined annual and promotional grant, expected February 11, 2027). Company simultaneously restructures into three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg, with three business unit leaders reporting to Fitzgerald.
Why this rating
Leadership succession and organizational restructuring are routine at large-cap companies; $7M equity and $1.05M salary are material for the individual but negligible relative to $158.7B market cap (0.004% of company value). No material business impact disclosed.
See more from October 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.